论文部分内容阅读
目的观察噻托溴铵治疗慢性阻塞性肺疾病急性加重期(AECOPD)临床疗效与安全性。方法选取2010年1月-2011年12月入院的69例AECOPD患者随机分为试验组(A组,n=36)和对照组(B组,n=33),A组在B组常规治疗的基础上吸入噻托溴铵。治疗起始及结束分别观察两组肺功能指标、慢性阻塞性肺疾病评估测试(CAT)评分、血气分析、6分钟步行距离、住院时间及药物不良反应。结果两组均显示出一定的临床效果,A组治疗后肺功能指标、CAT评分、血气分析、6分钟步行距离均优于B组,差异均具有统计学意义(P<0.05)。A组住院时间短于B组(P<0.05),且无严重不良反应。结论 AECOPD患者在常规治疗同时吸入噻托溴铵,疗效显著且临床安全性较高。
Objective To observe the clinical efficacy and safety of tiotropium in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Sixty-nine patients with AECOPD admitted to our hospital from January 2010 to December 2011 were randomly divided into experimental group (group A, n = 36) and control group (group B, n = 33). Group A received routine treatment in group B Based on inhaled tiotropium bromide. Pulmonary function indexes, chronic obstructive pulmonary disease evaluation test (CAT) score, blood gas analysis, 6-minute walking distance, hospital stay and adverse drug reactions were observed at the beginning and the end of treatment. Results Both groups showed some clinical effects. The pulmonary function index, CAT score, blood gas analysis and distance of 6 minutes walking in group A were better than those in group B (P <0.05). Group A hospitalization was shorter than group B (P <0.05), and no serious adverse reactions. Conclusions Patients with AECOPD inhaled tiotropium simultaneously with conventional therapy, with a significant effect and high clinical safety.